Selective loss of synaptic proteins in Alzheimer's disease: evidence for an increased severity with APOE varepsilon4.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Neurochemistry International

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 16814428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ApoE-dependent plasticity in Alzheimer’s disease

  2007cited by this paper
• Differential loss of synaptic proteins in Alzheimer's disease: Implications for synaptic dysfunction

  2005cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients.

  2003cited by this paper
• ApoE isoforms affect neuronal N-methyl-D-aspartate calcium responses and toxicity via receptor-mediated processes.

  2003cited by this paper
• Synaptic plasticity: the subcellular location of CaMKII controls plasticity.

  2003cited by this paper
• Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease.

  2003cited by this paper
• Structure-function of the multifunctional Ca2+/calmodulin-dependent protein kinase II.

  2002cited by this paper
• Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria

  2002cited by this paper
• Participation of CaMKII in Neuronal Plasticity and Memory Formation

  2002cited by this paper
• Apolipoprotein E and Alzheimer's disease: The protective effects of ApoE2 and E3

  2002cited by this paper
• Synaptic Pathology in Prefrontal Cortex is Present Only with Severe Dementia in Alzheimer Disease

  2001cited by this paper
• Synaptic loss is accompanied by an increase in synaptic area in the dentate gyrus of aged human apolipoprotein E4 transgenic mice.

  2000cited by this paper
• Molecular modification of N-cadherin in response to synaptic activity.

  2000cited by this paper
• Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease.

  2000cited by this paper
• Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease.

  2000cited by this paper
• Transfection analysis of functional roles of complexin I and II in the exocytosis of two different types of secretory vesicles.

  1999cited by this paper
• Immunohistochemical distribution of the two isoforms of synaphin/complexin involved in neurotransmitter release: localization at the distinct central nervous system regions and synaptic types.

  1999cited by this paper
• Loss of proteins regulating synaptic plasticity in normal aging of the human brain and in Alzheimer disease.

  1999cited by this paper
• N-Cadherin Redistribution during Synaptogenesis in Hippocampal Neurons

  1998cited by this paper
• Neurochemical Dissection of Synaptic Pathology in Alzheimer's Disease

  1998cited by this paper
• A role for the cadherin family of cell adhesion molecules in hippocampal long-term potentiation.

  1998cited by this paper
• Structural biology of cadherins in the nervous system.

  1998cited by this paper
• Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia.

  1998cited by this paper
• Cybrids in Alzheimer's disease: A cellular model of the disease?

  1997cited by this paper
• Mother's legacy: mitochondrial DNA mutations and Alzheimer's disease.

  1997cited by this paper
• The genetics of Alzheimer's disease.

  1997cited by this paper
• Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein.

  1997cited by this paper
• Neurites, synapses, and cadherins reconciled.

  1997cited by this paper
• Regulatory roles of complexins in neurotransmitter release from mature presynaptic nerve terminals

  1997cited by this paper
• Calcium Binds Dynamin I and Inhibits Its GTPase Activity

  1996cited by this paper
• Alterations in tau protein metabolism during normal aging.

  1996cited by this paper
• Disappearance of actin‐binding protein, drebrin, from hippocampal synapses in alzheimer's disease

  1996cited by this paper
• A novel enzyme-linked immunosorbent assay for determination of synaptophysin as compared with other quantification procedures.

  1996cited by this paper
• Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls.

  1996cited by this paper
• Cytochrome C Oxidase in Alzheimer's Disease Brain

  1995cited by this paper
• Induction of beta-amyloid-containing polypeptides in hippocampus: evidence for a concomitant loss of synaptic proteins and interactions with an excitotoxin.

  1994cited by this paper
• Phosphorylation of dynamin I and synaptic-vesicle recycling.

  1994cited by this paper
• Calcium/calmodulin-dependent protein kinase II immunostaining is preserved in Alzheimer's disease hippocampal neurons.

  1994cited by this paper
• Functional Alterations in Alzheimer's Disease: Selective Loss of Mitochondrial-encoded Cytochrome Oxidase mRNA in the Hippocampal Formation

  1994cited by this paper
• Biochemical and anatomical redistribution of tau protein in Alzheimer's disease.

  1993cited by this paper
• Regional synaptic pathology in Alzheimer's disease.

  1992cited by this paper
• Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles.

  1992cited by this paper
• Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

  1990cited by this paper
• Quantitative assessment of cortical synaptic density in Alzheimer's disease.

  1990cited by this paper
• Cytochrome oxidase deficiency in Alzheimer's disease

  1990cited by this paper
• The multisubunit structure of synaptophysin. Relationship between disulfide bonding and homo-oligomerization.

  1990cited by this paper
• Quantitative immunohistochemistry of synaptophysin in human neocortex: an alternative method to estimate density of presynaptic terminals in paraffin sections.

  1990cited by this paper
• Synaptic loss in Alzheimer's disease and other dementias

  1989cited by this paper
• Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease.

  1989cited by this paper
• Optimization of freezing, storage, and thawing conditions for the preparation of metabolically active synaptosomes from frozen rat and human brain.

  1986cited by this paper
• Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles.

  1985cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Navigation Between Alzheimer’s Disease (AD) and Its Various Pathophysiological Trajectories: The Pathogenic Link to Neuroimmunology—Genetics and Neuroinflammation

  2025cites this paper
• Therapeutic Role of Scutellarein in Neurological Disorders.

  2025cites this paper
• Ligature-induced periodontitis in a transgenic mouse model of Alzheimer's disease dysregulates neuroinflammation, exacerbates cognitive impairment, and accelerates amyloid pathology

  2025cites this paper
• CSF neurogranin levels as a biomarker in Alzheimer’s disease and frontotemporal lobar degeneration: a cross-sectional analysis

  2024cites this paper
• The HOPE4MCI study: A randomized double‐blind assessment of AGB101 for the treatment of MCI due to AD

  2024cites this paper
• Associations of brain morphology with cortical proteins of cognitive resilience.

  2024cites this paper
• Apolipoprotein E in Alzheimer’s Disease: Focus on Synaptic Function and Therapeutic Strategy

  2024cites this paper
• SV2A PET shows hippocampal synaptic loss in cognitively unimpaired APOE ε4/ε4 homozygotes

  2024cites this paper
• CaMKII activity and metabolic imbalance-related neurological diseases: Focus on vascular dysfunction, synaptic plasticity, amyloid beta accumulation, and lipid metabolism.

  2024cites this paper
• Functional connectivity favors hyperactivity leading to synapse loss in amyloidosis

  2023cites this paper
• Structure, function, and pathology of Neurexin-3

  2022influential citation
• Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk

  2021cites this paper
• The detrimental effects of APOE4 on risk for Alzheimer's disease may result from altered dendritic spine density, synaptic proteins, and estrogen receptor alpha.

  2021cites this paper
• Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives

  2021cites this paper
• The role of synaptic microRNAs in Alzheimer's disease.

  2020cites this paper
• Efficacy of Sulforaphane in Neurodegenerative Diseases

  2020cites this paper
• Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25.

  2020cites this paper
• Dysfunctional proteins in neuropsychiatric disorders: from neurodegeneration to Autism Spectrum Disorders.

  2020cites this paper
• Systems biology reveals reprogramming of the S-nitroso-proteome in the cortical and striatal regions of mice during aging process

  2020cites this paper
• Research progress on the role of type I vesicular glutamate transporter (VGLUT1) in nervous system diseases

  2020cites this paper
• Cognitively Normal APOE ε4 Carriers Have Speci�c Elevation of CSF SNAP-25

  2020cites this paper
• Proteomic alterations of brain subcellular organelles caused by low-dose copper exposure: implication for Alzheimer’s disease

  2018cites this paper
• Edinburgh Research Explorer APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer's disease

  2018cites this paper
• Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognition

  2018cites this paper
• Invited Review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer's disease

  2018cites this paper
• Implications of Successful Symptomatic Treatment in Parkinson's Disease for Therapeutic Strategies of Alzheimer's Disease.

  2018cites this paper
• Mitochondrial Molecular Abnormalities Revealed by Proteomic Analysis of Hippocampal Organelles of Mice Triple Transgenic for Alzheimer Disease

  2018cites this paper
• Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets

  2017cites this paper
• Melatonin ameliorates anxiety and depression‐like behaviors and modulates proteomic changes in triple transgenic mice of Alzheimer's disease

  2017cites this paper
• Effect of APOE Genotype on Synaptic Proteins in Earlier Adult Life

  2017cites this paper
• ERβ and ApoE isoforms interact to regulate BDNF–5-HT2A signaling and synaptic function in the female brain

  2017cites this paper
• Quantitative Proteomics Reveals the Mechanism of Oxygen Treatment on Lenses of Alzheimer’s Disease Model Mice

  2016cites this paper
• Meta‐analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability

  2016cites this paper
• Increased complexin-1 and decreased miR-185 expression levels in Behçet’s disease with and without neurological involvement

  2016cites this paper
• Neuronal Gene Targets of NF-κB and Their Dysregulation in Alzheimer's Disease

  2016cites this paper
• Truncated tau deregulates synaptic markers in rat model for human tauopathy

  2015influential citation
• Calcium/calmodulin-dependent kinase II and Alzheimer’s disease

  2015cites this paper
• An overview on neuroprotective effects of isothiocyanates for the treatment of neurodegenerative diseases.

  2015cites this paper
• Identification of the Key Molecules Involved in Chronic Copper Exposure-Aggravated Memory Impairment in Transgenic Mice of Alzheimer's Disease Using Proteomic Analysis

  2015cites this paper
• MicroRNA-34c Downregulation Ameliorates Amyloid-β-Induced Synaptic Failure and Memory Deficits by Targeting VAMP2

  2015cites this paper
• New insights into Alzheimer's disease pathogenesis: the involvement of neuroligins in synaptic malfunction.

  2015cites this paper
• Synaptic protein levels altered in vascular dementia

  2015cites this paper
• Genetics of Posttraumatic Stress Disorder — Candidate Genes and Their Implication in the Disease-Associated Molecular Pathomechanisms

  2015cites this paper
• Role for the neurexin-neuroligin complex in Alzheimer's disease.

  2014cites this paper
• Cofilin Rods and Aggregates Concur with Tau Pathology and the Development of Alzheimer's Disease

  2014cites this paper
• Dynamin protein in stroke and vascular dementia.

  2014cites this paper
• Cognitive Enhancing Treatment with a PPARγ Agonist Normalizes Dentate Granule Cell Presynaptic Function in Tg2576 APP Mice

  2014cites this paper
• Is synaptic loss a unique hallmark of Alzheimer's disease?

  2014cites this paper
• Complexin2 modulates working memory-related neural activity in patients with schizophrenia

  2014cites this paper
• Involvement of Anomalous Apoptosis in Impairments to Synaptic Plasticity in Post-Traumatic Stress Disorder

  2014cites this paper
• Opposing actions of environmental enrichment and Alzheimer's disease on the expression of hippocampal microRNAs in mouse models

  2013cites this paper
• Sulforaphane as a Potential Protective Phytochemical against Neurodegenerative Diseases

  2013cites this paper
• [The involvement of abnormal apoptosis in the disturbance of synaptic plasticity in posttraumatic stress disorder].

  2013cites this paper
• Axonal and synaptic pathology in Alzheimer’s disease

  2013cites this paper
• Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action

  2012cites this paper
• Dynamics of subcellular proteomes during brain development.

  2012cites this paper
• Cognitive reserve, presynaptic proteins and dementia in the elderly

  2012cites this paper
• Tau-Mediated Nuclear Depletion and Cytoplasmic Accumulation of SFPQ in Alzheimer's and Pick's Disease

  2012cites this paper
• Tensor-Based Morphometry and Stereology Reveal Brain Pathology in the Complexin1 Knockout Mouse

  2012cites this paper
• One-Carbon Metabolism Alteration Affects Brain Proteome Profile in a Mouse Model of Alzheimer's Disease

  2011cites this paper
• Dysregulated phosphorylation of Ca2+/calmodulin‐dependent protein kinase II‐α in the hippocampus of subjects with mild cognitive impairment and Alzheimer’s disease

  2011cites this paper
• Phenotype-based genetic association studies in schizophrenia: proof-of-principle for cognition-relevant genes

  2011cites this paper
• Post-synaptic scaffolding protein interactions with glutamate receptors in synaptic dysfunction and Alzheimer's disease.

  2011cites this paper
• Synaptic Loss in the Inferior Temporal Gyrus in Mild Cognitive Impairment and Alzheimer's Disease

  2011cites this paper
• Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease.

  2011cites this paper
• Changed Clathrin Regulatory Proteins in the Brains of Alzheimer's Disease Patients and Animal Models

  2010cites this paper
• Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse.

  2010cites this paper
• Reduction in Post-Synaptic Scaffolding PSD-95 and SAP-102 Protein Levels in the Alzheimer Inferior Temporal Cortex is Correlated with Disease Pathology

  2010cites this paper
• Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease.

  2010cites this paper
• Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms.

  2010cites this paper
• Localization of CD226 in the mouse hippocampus and cerebellum during adulthood and postnatal development.

  2009cites this paper
• Independent alterations in the central and peripheral somatosensory pathways in rat diabetic neuropathy.

  2009cites this paper
• Type-2 alkenes mediate synaptotoxicity in neurodegenerative diseases.

  2008cites this paper
• Apolipoprotein E Highly Correlates with AβPP- and Tau-Related Markers in Human Cerebrospinal Fluid

  2008cites this paper
• Apolipoprotein E4 domain interaction: Synaptic and cognitive deficits in mice

  2008cites this paper
• For Better or for Worse: Complexins Regulate SNARE Function and Vesicle Fusion

  2008cites this paper
• Purple sweet potato color repairs d-galactose-induced spatial learning and memory impairment by regulating the expression of synaptic proteins.

  2008cites this paper
• Reduced Expression of the Inhibitory Synapse Scaffolding Protein Gephyrin in Alzheimer's Disease

  2008cites this paper
• Altered complexin expression in psychiatric and neurological disorders: cause or consequence?

  2008cites this paper
• Assessment of post‐mortem‐induced changes to the mouse brain proteome

  2008cites this paper
• Risk and protective factors for sporadic Alzheimer's disease.

  2007cites this paper
• Complexin 1 knockout mice exhibit marked deficits in social behaviours but appear to be cognitively normal.

  2007cites this paper
• Neurobiology of Aging

  year unknowncites this paper
• Spotlight on the Pathophysiological Trajectories Linked toAlzheimer’s Disease (AD): Blood-Brain Barrier (BBB);Neuroinflammation; APOE4 Allele and AD-Insulin Resistance (IR) Pathogenic Link

  year unknowncites this paper